local_hospital

Zuyderland Medisch Centrum Stichting

Address
lock Available on a paid plan

Oncology and Hematologic Malignancies

At Zuyderland Medisch Centrum Stichting, research in neoplasms and blood cancers focuses on improving treatment outcomes for patients with a wide range of solid tumors and hematologic malignancies. The studies explore new combinations and treatment strategies for cancers such as breast cancer, non-small cell lung cancer, gastric cancer, urothelial cancer, melanoma, and multiple forms of leukemia and lymphoma.

  • Testing new cancer therapies and combination approaches to improve survival and disease control
  • Evaluating treatment effectiveness in advanced breast cancer, prostate cancer, and lung cancer
  • Studying better options for acute myeloid leukemia, chronic lymphocytic leukemia, multiple myeloma, and diffuse large B-cell lymphoma

These trials reflect a strong focus on refining cancer care through more effective and personalized treatment approaches.

Neurology and Multiple Sclerosis Research

Clinical research in nervous system diseases is especially active in multiple sclerosis, with studies covering relapsing, progressive, and primary progressive disease forms. The work aims to better control disease activity, slow disability progression, and assess the long-term safety and effectiveness of treatments used in everyday care.

  • Assessing therapies for relapsing multiple sclerosis, progressive multiple sclerosis, and primary progressive multiple sclerosis
  • Evaluating long-term safety and real-world effectiveness of established multiple sclerosis treatments
  • Exploring personalized treatment approaches to improve disease control and reduce disability

This area highlights the site’s interest in both new and ongoing strategies for people living with chronic neurological disease.

Gastroenterology and Inflammatory Bowel Disease

Research in digestive system diseases includes studies for ulcerative colitis and Crohn’s disease, with attention to symptom control, endoscopic response, and longer-term safety of treatment options. The goal is to improve everyday disease management for people with chronic intestinal inflammation.

  • Testing new therapies for mild-to-moderate ulcerative colitis and more active forms of Crohn’s disease
  • Measuring how well treatments reduce intestinal inflammation and improve clinical remission
  • Following longer-term safety and tolerability of therapies used for chronic bowel disease

These studies support more effective and better-tolerated care for patients with long-standing gastrointestinal disease.

Urology, Prostate Cancer, and Kidney Health

The site also conducts research across male urogenital diseases and cardiovascular and kidney-related conditions, including studies in metastatic castration-resistant prostate cancer, metastatic hormone-sensitive prostate cancer, and chronic kidney disease. This work aims to improve survival, delay progression, and better manage major complications.

  • Evaluating new treatment strategies for advanced prostate cancer
  • Studying therapies intended to improve kidney and heart-related outcomes in high-risk patients
  • Exploring ways to better control disease progression and support long-term care

These trials show a broad interest in conditions that often require coordinated, long-term internal medicine care.

Endocrinology, Reproductive Health, and Symptom Management

Research in hormonal diseases and reproductive and urinary physiological phenomena includes studies on hypothyroidism, polycystic ovary syndrome, and treatment-related fatigue. The focus is on improving symptoms, quality of life, and the day-to-day impact of chronic endocrine disorders.

  • Comparing treatment approaches for persistent tiredness in autoimmune hypothyroidism
  • Studying fertility-related treatment strategies in polycystic ovary syndrome
  • Assessing whether tailored care can better match treatment to individual patient needs

At this hospital-based research site, these studies aim to make chronic hormone-related conditions easier to live with.

Musculoskeletal, Thrombosis, and Public Health Studies

Work in musculoskeletal diseases and environment and public health includes research on preventing venous thromboembolism after joint replacement, alongside studies that look at broader care organization and treatment safety. The aim is to improve prevention strategies and support safer recovery for patients.

  • Comparing thrombosis prevention approaches after hip and knee arthroplasty
  • Studying which patients may benefit from more individualized prevention plans
  • Evaluating ways to improve patient safety and care efficiency in routine practice

These trials add a practical, prevention-focused dimension to the research portfolio at Zuyderland Medisch Centrum Stichting.

Site Overview

assignment
139
connected trials
corporate_fare
62
sponsors
science
340
IMPs

Activity Indicator

Last 6 months

12
Trials started
+100% vs previous period.
6
Trials started 6–12 months ago
139
Total trials linked
Highly Active
trending_upGrowing+100%
1
3
2
5
1
Mar
Apr
May
Jun
Jul
Aug

Trial Flow

How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.

Therapeutic areaarrow_forwardIMParrow_forwardLifecycle status

Top 5 of 20 therapeutic areas and 15 of 340 IMPs, ranked by number of trials.

lock Available on a paid plan

Compounds & Molecules Timeline

The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.

Trial span Ongoing Showing last 8 years

Top 40 of 335 compounds, ranked by number of trials.

lock Available on a paid plan

Sponsor & Partnership

Top sponsors by active trials, and the ones that have come back for more than one study.

Active trials
69
Sponsors (total)
62
Active sponsors
42

Sponsor Network

Top 42 by active trials.

Partnership History

Sponsors with repeated collaboration (≥ 2 trials).

lock +29 more on a paid plan

Sponsor Network Graph

How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.

Country Benchmark

Compared to 271 other sites in The Netherlands

description
Trial volume
139
Outperforms 95% of sites
public
Therapeutic diversity
20areas
Outperforms 89% of sites
groups
Sponsor diversity
62sponsors
Outperforms 94% of sites

Therapeutic Area Benchmark — The Netherlands

Select a therapeutic area to compare against other sites in The Netherlands.

Competitor Comparison

Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.

Country: The Netherlands

Market Share

Country: The Netherlands

Therapeutic Area Market Share

Select a therapeutic area to view its disease coverage breakdown.

Heat Maps & Advanced Analytics

How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.

Other Trials in Zuyderland Medisch Centrum Stichting

lock Showing 1 of 139 trials — the rest is available on a paid plan.

Trial Sponsor Phase Status Start Date End Date
(20321) An open-label, single arm, roll-over study to provide continued treatment with darolutamide in participants who were enrolled in previous Bayer sponsored studiesBayer Consumer Care AGPhase IIINot RecruitingOct 2020

IMP list

lock Showing 1 of 340 compounds — the rest is available on a paid plan.

IMP Trials Status First start Last start
Pembrolizumab11Unknown2015-11-062026-07-08

Upgrade this site to Business Plan

Own the profile, publish your feasibility data and reach sponsors directly.

Is something out of date?

Tell us what needs correcting and we'll update this profile.

lock Available to Business plan sites only.